hi humble Voyager,
would you please tell me the facts and the names of the people who have died because of 5 + maoi?
in yopo it is used maoi and no problem, the danger is if 5 is taken orally with maoi , NOT RECTALLY.
Will you please tell me where from did you get this information? thanks
all the best. celestino
AbstractA case of a 25-year-old white male who was found dead the morning after consuming herbal extracts containing betacarbolines and hallucinogenic tryptamines is presented. No anatomic cause of death was found at autopsy. Toxicologic analysis of the heart blood identified N,N-dimethyltryptamine (0.02 mg/L), 5-methoxy-N,Ndimethyltryptamine (1.88 rag/L), tetrahydroharmine (0.38 rag/t), harmaline (0.07 mg/L), and harmine (0.17 mg/L). All substances were extracted by a single-step n-butyl chloride extraction following alkalinization with borate buffer. Detection and quantitation was performed using liquid chromatographyelectrospray mass spectrometry. The medical examiner ruled that the cause of death was hallucinogenic amine intoxication, and the manner of death was undetermined.
To read the full paper refer to this source:
https://sci-hub.tw/10.1093/jat/29.8.838Further studies point to toxicity in combination with an MAOI:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028383/"At the pharmacokinetic level, a perpetrator drug alters the absorption, disposition, metabolism, or excretion of the victim drug, which may be translated into a significant change in drug efficacy and/or toxicity. The metabolic DDI is often observed because metabolism represents the major route of drug elimination. At the pharmacodynamic level, concurrent drugs both act on the common targets, leading to synergistic or antagonistic responses. It should be noted that some drugs may interact at both pharmacokinetic and pharmacodynamic levels, and lead to severe or even fatal toxicity. This may be true for the concomitant use of 5-MeO-DMT and harmaline or another MAOI. By inhibiting MAO-A-mediated 5-HT degradation, MAOI itself promotes serotonergic transmission (Fig. 2). Furthermore, harmaline is also a 5-HT agonist [96, 97] that could potentiate serotonergic actions of 5-MeO-DMT. In addition, harmaline reduces 5-MeO-DMT deamination metabolism, leading to an increased and prolonged exposure to 5-MeO-DMT, as well as the psychoactive metabolite bufotenine that depends upon CYP2D6 status. Indeed, cases of severe and lethal intoxication due to the combined use of a tryptamine (e.g., 5-MeO-DMT or 5-MeO-DiPT) and an MAOI drug (e.g., harmaline) have been reported [38, 39, 98, 99]."
Further reading about this can be found here:
https://erowid.org/chemicals/5meo_dmt/5meo_dmt_death.shtml